, Volume 40, Issue 6, pp 1875–1883 | Cite as

NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid

  • Can Cai
  • Xiwen Zhu
  • Peizhi Li
  • Jinzheng Li
  • Jianping Gong
  • Wei Shen
  • Kun HeEmail author


The cleavage and secretion of pro-inflammatory cytokines IL-1β and IL-18 is regulated by NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome activation. Kupffer cells (KCs) are implicated in the pathogenesis of various liver diseases, such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and liver fibrosis. However, the role of NLRP3 played in the non-alcoholic steatohepatitis (NASH) has yet to be evaluated. In the present study, methionine–choline-deficient (MCD) diet was used to establish the mice NASH model. The expression levels of F4/80 and NLRP3 in liver tissues were evaluated, and the IL-1β and IL-18 in serum were also evaluated. KCs were isolated from wild-type (WT) mice and NLRP3 knockout (NLRP3−/−) mice and then randomly divided into two groups: the control and palmitic acid (PA) groups. The expression levels of NLRP3, ASC, and caspase-1 in KCs were determined by RT-PCR, western blotting, and immunofluorescence. The levels of IL-1β and IL-18 in the supernatant (SN) of KCs were evaluated by enzyme-linked immunosorbent assay (ELISA). We found that KCs and NLRP3 play pro-inflammatory roles in the progression of NASH, probably through secretions of IL-1β and IL-18 by KCs induced by PA. PA could act as a kind of damage-associated molecular patterns to elevate the messenger RNA and protein expression levels of NLRP3, ASC, and caspase-1 in KCs from WT mice. In the contrast, NLRP3 deletion could inhibit the NLRP3 inflammasome upregulation and activation in KCs induced by PA. Furthermore, the levels of pro-inflammatory cytokines IL-1β and IL-18 in the SN of KCs from WT mice were all elevated with the stimulation of PA, and the increase of these cytokines in the SN was blocked by NLRP3 deletion. In conclusion, our novel findings demonstrate that NLRP3 plays a pivotal role in NASH development and pro-inflammatory cytokines IL-1β and IL-18 secretion induced by PA stimulation, and NLRP3 might be an effective potential target for the treatment of liver inflammatory diseases associated with NLRP3 inflammasome activation.


non-alcoholic fatty liver disease NLRP3 inflammasome IL-1β Kupffer cell palmitic acid 



The work was supported by the National Nature Science Foundation of China (No. 81400614 and No. 31370753).

Compliance with Ethical Standards

The animals received humane care in compliance with the institution’s guidelines, as outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences. All experimental protocols described in this study complied with the ethics review committee for animal experimentation of Chongqing Medical University.

Conflict of Interest

The authors declare that they have no competing interests.


  1. 1.
    European Association for the Study of the Liver (EASL).; European Association for the Study of Diabetes (EASD).; European Association for the Study of Obesity (EASO). 2016. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology 64 (6): 1388–1402.CrossRefGoogle Scholar
  2. 2.
    Wree, A., L. Broderick, A. Canbay, H.M. Hoffman, and A.E. Feldstein. 2013. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nature Reviews. Gastroenterology & Hepatology 10: 627–636.CrossRefGoogle Scholar
  3. 3.
    Wong, R.J., R. Cheung, and A. Ahmed. 2014. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59: 2188–2195.CrossRefPubMedGoogle Scholar
  4. 4.
    Day, C.P., and O.F. James. 1998. Steatohepatitis: A tale of two “hits”? Gastroenterology 114: 842–845.CrossRefPubMedGoogle Scholar
  5. 5.
    Seki, E., and R.F. Schwabe. 2015. Hepatic inflammation and fibrosis: Functional links and key pathways. Hepatology 61: 1066–1079.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pais, R., F. Charlotte, L. Fedchuk, P. Bedossa, P. Lebray, T. Poynard, et al. 2013. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology 59: 550–556.CrossRefPubMedGoogle Scholar
  7. 7.
    Latz, E., T.S. Xiao, and A. Stutz. 2013. Activation and regulation of the inflammasomes. Nature Reviews. Immunology 13 (6): 397–411.CrossRefPubMedGoogle Scholar
  8. 8.
    Lamkanfi, M., and V.M. Dixit. 2012. Inflammasomes and their roles in health and disease. Annual Review of Cell and Developmental Biology 28: 137–161.CrossRefPubMedGoogle Scholar
  9. 9.
    Strowig, T., J. Henao-Mejia, E. Elinav, and R. Flavell. 2012. Inflammasomes in health and disease. Nature 481 (7381): 278–286.CrossRefPubMedGoogle Scholar
  10. 10.
    Elliott, E.I., and F.S. Sutterwala. 2015. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunological Reviews 265 (1): 35–52.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Csak, T., M. Ganz, J. Pespisa, et al. 2011. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54 (1): 133–144.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Miura, K., L. Yang, N. van Rooijen, et al. 2013. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 57 (2): 577–589.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jenne, C.N., and P. Kubes. 2013. Immune surveillance by the liver. Nature Immunology 14 (10): 996–1006.CrossRefPubMedGoogle Scholar
  14. 14.
    Wynn, T.A., A. Chawla, and J.W. Pollard. 2013. Macrophage biology in development, homeostasis and disease. Nature 496 (7446): 445–455.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Li, P., K. He, J. Li, et al. 2017. The role of Kupffer cells in hepatic diseases. Molecular Immunology 85: 222–229.CrossRefPubMedGoogle Scholar
  16. 16.
    Heymann, F., and F. Tacke. 2016. Immunology in the liver—from homeostasis to disease. Nature Reviews. Gastroenterology & Hepatology 13 (2): 88–110.CrossRefGoogle Scholar
  17. 17.
    Tiniakos, D.G., M.B. Vos, and E.M. Brunt. 2010. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annual Review of Pathology 5: 145–171.CrossRefPubMedGoogle Scholar
  18. 18.
    Szabo, G., and T. Csak. 2012. Inflammasomes in liver diseases. Journal of Hepatology 57 (3): 642–654.CrossRefPubMedGoogle Scholar
  19. 19.
    Hoque, R., Y. Vodovotz, and W. Mehal. 2013. Therapeutic strategies in inflammasome mediated diseases of the liver. Journal of Hepatology 58 (5): 1047–1052.CrossRefPubMedGoogle Scholar
  20. 20.
    Li, P.Z., J.Z. Li, M. Li, et al. 2014. An efficient method to isolate and culture mouse Kupffer cells. Immunology Letters 158 (1–2): 52–56.CrossRefPubMedGoogle Scholar
  21. 21.
    Racanelli, V., and B. Rehermann. 2006. The liver as an immunological organ. Hepatology 43 (2 Suppl 1): S54–S62.CrossRefPubMedGoogle Scholar
  22. 22.
    Lamkanfi, M., and V.M. Dixit. 2014. Mechanisms and functions of inflammasomes. Cell 157 (5): 1013–1022.CrossRefPubMedGoogle Scholar
  23. 23.
    Jin, C., J. Henao-Mejia, and R.A. Flavell. 2013. Innate immune receptors: Key regulators of metabolic disease progression. Cell Metabolism 17 (6): 873–882.CrossRefPubMedGoogle Scholar
  24. 24.
    Baffy, G. 2009. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. Journal of Hepatology 51 (1): 212–223.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Stienstra, R., F. Saudale, C. Duval, et al. 2010. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 51 (2): 511–522.CrossRefPubMedGoogle Scholar
  26. 26.
    Bilzer, M., F. Roggel, and A.L. Gerbes. 2006. Role of Kupffer cells in host defense and liver disease. Liver International 26 (10): 1175–1186.CrossRefPubMedGoogle Scholar
  27. 27.
    Broz, P., and V.M. Dixit. 2016. Inflammasomes: Mechanism of assembly, regulation and signalling. Nature Reviews. Immunology 16 (7): 407–420.CrossRefPubMedGoogle Scholar
  28. 28.
    Guo, H., J.B. Callaway, and J.P. Ting. 2015. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nature Medicine 21 (7): 677–687.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Can Cai
    • 1
  • Xiwen Zhu
    • 2
  • Peizhi Li
    • 2
  • Jinzheng Li
    • 2
  • Jianping Gong
    • 2
  • Wei Shen
    • 1
  • Kun He
    • 2
    Email author
  1. 1.Department of Gastroenterology and HepatologyThe Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina
  2. 2.Department of Hepatobiliary SurgeryThe Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations